We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+3.36%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$737M
(+20%)
Cap. Flow
+$736M
Cap. Flow
% of AUM
16.32%
Top 10 Holdings %
Top 10 Hldgs %
19.25%
Holding
501
New
284
Increased
70
Reduced
66
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$99.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$80.7M |
| 3 |
Johnson & Johnson
JNJ
|
+$77.7M |
| 4 |
Electronic Arts
EA
|
+$61.9M |
| 5 |
Danaher
DHR
|
+$60.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$99.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$97.8M |
| 3 |
Medtronic
MDT
|
+$68.7M |
| 4 |
NXP Semiconductors
NXPI
|
+$61.6M |
| 5 |
Lumentum
LITE
|
+$58.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.83% |
| 2 | Technology | 26.25% |
| 3 | Communication Services | 6.68% |
| 4 | Consumer Discretionary | 4.05% |
| 5 | Financials | 2.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DMYQ.U
76
DELISTED
dMY Technology Group, Inc. IV Units, each consisting of one share of Class A common stock and one-fi
DMYQ.U
| $17.2M | 0.38% |
+1,717,205
| New | +$17.5M |
|
77
Acadia Healthcare
ACHC
$2.85B
| $17.2M | 0.38% |
300,389
+247,103
| +464% | +$13.4M |
|
78
Edgewell Personal Care
EPC
$1.27B
| $17M | 0.38% |
428,921
+3,512
| +0.8% | +$122K |
|
79
Alkermes
ALKS
$8.31B
| $16.3M | 0.36% |
871,560
-1,269,809
| -59% | -$26M |
|
80
ICU Medical
ICUI
$4.32B
| $16.1M | 0.36% |
78,475
+9,216
| +13% | +$1.95M |
|
81
AbbVie
ABBV
$433B
| $15.3M | 0.34% |
+141,235
| New | +$15.1M |
|
82
HP
HPQ
$24.8B
| $15.2M | 0.34% |
479,467
+314,769
| +191% | +$8.69M |
|
83
Jabil
JBL
$33.4B
| $14.9M | 0.33% |
286,068
+84,653
| +42% | +$3.86M |
|
84
Applied Materials
AMAT
$411B
| $14.7M | 0.33% |
110,076
-508,341
| -82% | -$56.1M |
|
|
MTEM
85
DELISTED
Molecular Templates, Inc.
MTEM
| $14.5M | 0.32% |
76,368
+41,857
| +121% | +$7.34M |
|
86
Immunovant
IMVT
$7.91B
| $14.4M | 0.32% |
896,617
+594,714
| +197% | +$15.7M |
|
87
Western Digital
WDC
$182B
| $14.2M | 0.32% |
+281,646
| New | +$13.2M |
|
88
Semtech
SMTC
$11.1B
| $14.2M | 0.31% |
205,323
+102,239
| +99% | +$7.5M |
|
|
HOLX
89
DELISTED
Hologic
HOLX
| $13.6M | 0.3% |
182,958
-164,766
| -47% | -$12.5M |
|
90
Exelixis
EXEL
$13.8B
| $13.5M | 0.3% |
598,308
+325,508
| +119% | +$7.35M |
|
91
Sana Biotechnology
SANA
$885M
| $13.5M | 0.3% |
+401,994
| New | +$13.1M |
|
92
Atea Pharmaceuticals
AVIR
$369M
| $13.3M | 0.3% |
215,673
-60,410
| -22% | -$4.08M |
|
|
APTO
93
DELISTED
Aptose Biosciences, Inc.
APTO
| $13.3M | 0.29% |
4,930
+2,792
| +131% | +$5.54M |
|
|
SWTX
94
DELISTED
SpringWorks Therapeutics
SWTX
| $12.9M | 0.29% |
175,328
+45,496
| +35% | +$3.56M |
|
|
BHVN
95
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $12.9M | 0.29% |
+188,256
| New | +$15.2M |
|
|
DOYU
96
DouYu International Holdings
DOYU
$142M
| $12.7M | 0.28% |
121,888
-47,681
| -28% | -$6.46M |
|
97
Encompass Health
EHC
$11.2B
| $12.6M | 0.28% |
193,827
-43,688
| -18% | -$2.85M |
|
98
PTC Therapeutics
PTCT
$5.68B
| $12.4M | 0.27% |
261,534
+141,063
| +117% | +$8.38M |
|
99
Bolt Biotherapeutics
BOLT
$7.65M
| $12.3M | 0.27% |
+18,706
| New | +$12.2M |
|
100
Edgewise Therapeutics
EWTX
$4.13B
| $11.6M | 0.26% |
+357,429
| New | +$11.6M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Woodline Partners held 501 positions worth $4.51B, up 20% from $3.77B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Woodline Partners deployed $736M of net new capital in Q1 2021, opening 284 new positions and adding to 70 existing holdings. Its largest new stake was Gilead Sciences: 1,541,893 shares worth $99.7M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Amgen, an estimated $99.3M trimmed.
- Woodline Partners's largest Q1 2021 buy was Gilead Sciences: 1,541,893 shares worth $99.7M.
- Woodline Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $80.7M increase.
- Woodline Partners's biggest Q1 2021 reduction was Amgen, cutting an estimated $99.3M.
- Woodline Partners fully exited Alphabet (Google) Class A in Q1 2021, selling an estimated $97.8M.
- Woodline Partners's ten largest holdings make up 19% of its $4.51B portfolio in Q1 2021.
- Woodline Partners opened 284 new positions and closed 74 in Q1 2021.
- Woodline Partners's portfolio value rose 20% quarter-over-quarter to $4.51B.
Based on Woodline Partners's 13F filing for Q1 2021, filed 17 May 2021.